Osmosis Investment Management UK Ltd Acquires New Holdings in Kenvue Inc. $KVUE

Osmosis Investment Management UK Ltd bought a new position in shares of Kenvue Inc. (NYSE:KVUE) during the second quarter, Holdings Channel reports. The fund bought 139,015 shares of the company’s stock, valued at approximately $2,657,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Johnson Financial Group Inc. purchased a new position in shares of Kenvue during the 2nd quarter valued at $26,000. CoreCap Advisors LLC increased its holdings in shares of Kenvue by 64.9% in the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after purchasing an additional 591 shares during the period. Elyxium Wealth LLC purchased a new stake in shares of Kenvue in the fourth quarter worth $26,000. Physician Wealth Advisors Inc. raised its position in shares of Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares in the last quarter. Finally, MV Capital Management Inc. purchased a new stake in shares of Kenvue in the fourth quarter worth $28,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Kenvue Stock Performance

Kenvue stock opened at $19.08 on Monday. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $21.78. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. The stock has a market cap of $36.65 billion, a P/E ratio of 21.93, a price-to-earnings-growth ratio of 1.36 and a beta of 0.47. The firm’s fifty day moving average price is $19.05 and its 200-day moving average price is $18.20.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). The company had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.97 billion. Kenvue had a return on equity of 21.22% and a net margin of 10.76%.The firm’s revenue was up 3.0% on a year-over-year basis. During the same quarter last year, the firm posted $0.29 earnings per share. On average, equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be paid a dividend of $0.21 per share. This represents a $0.84 annualized dividend and a yield of 4.4%. This is an increase from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Wednesday, August 12th. Kenvue’s dividend payout ratio is presently 96.55%.

Analysts Set New Price Targets

Several equities analysts recently commented on KVUE shares. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, June 15th. Zacks Research lowered Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Wall Street Zen cut Kenvue from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Barclays lifted their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Finally, UBS Group cut their price objective on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Three equities research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.